FLT3
10 drugsFMS-Like Tyrosine Kinase 3
Predictive biomarker for patient selection in 19 indications
Understanding FLT3
What it means: FLT3 mutations (ITD insertions, TKD point mutations) cause constitutive kinase activation. Found in ~30% of AML patients.
Why it matters: FLT3 inhibitors (midostaurin, gilteritinib, quizartinib) improve outcomes when added to chemotherapy or as monotherapy.
Testing: Tested via PCR (ITD) and sequencing (TKD). Allelic ratio of ITD affects prognosis. Tested at diagnosis and relapse.
10
Approved Drugs
19
Indications
9
Companies
FLT3 is a precision-medicine biomarker linked to 10 FDA-approved targeted drugs from 9 companies, spanning 19 indications including Myelofibrosis, Metastatic RET fusion-positive non-small cell lung cancer, Advanced or metastatic RET fusion-positive thyroid cancer. Explore the targeted therapies, indications, testing methods, and companies developing FLT3 drugs below.
Search FLT3 Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting FLT3
| Drug | Company | Therapeutic Area |
|---|---|---|
| GAVRETO | BLUEPRINT MEDICINES | Oncology |
| ICLUSIG | Takeda | Oncology |
| INREBIC | Bristol-Myers Squibb | Oncology |
| RYDAPT | Novartis | Oncology |
| SUNITINIB MALATE | FOSUN WANBANG | Oncology |
| SUTENT | CPPI CV | Oncology |
| TURALIO | DAIICHI SANKYO INC | Oncology |
| VANFLYTA | DAIICHI SANKYO INC | Oncology |
| VONJO | SOBI | Oncology |
| XOSPATA | ASTELLAS | Oncology |
FLT3 Indications
Myelofibrosis Metastatic RET fusion-positive non-small cell lung cancer Advanced or metastatic RET fusion-positive thyroid cancer Gastrointestinal Stromal Tumor Renal Cell Carcinoma Pancreatic Neuroendocrine Tumor Tenosynovial Giant Cell Tumor Gastrointestinal stromal tumor (GIST) Advanced renal cell carcinoma (RCC) Adjuvant treatment of renal cell carcinoma (RCC) at high risk of recurrence following nephrectomy Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) Acute Myeloid Leukemia Aggressive Systemic Mastocytosis Systemic Mastocytosis with Associated Hematological Neoplasm Mast Cell Leukemia Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Polycythemia Vera Essential Thrombocythemia